ProCE Banner Series

APPlexus Spring 2025

APPlexus is an initiative designed to address educational needs specific to advanced practice providers who care for patients with cancer. These webinars will navigate insights and updates for CAR T-cell therapy for hematologic malignancies, managing adverse events of immune checkpoint inhibitors alone and in combination with chemotherapy and targeted therapies, and review novel antibody–drug conjugates as treatments for breast cancer, while delivering innovative, real-time education to nurse practitioners, nurses, physician associates, and other healthcare professionals who care for these patients.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.

All Events

APPlexus Spring 2025

Upcoming Events

March

22

2025

9:00 AM - 1:15 PM Eastern Time (ET)

Virtual

Topics

Hematologic Malignancies

Breast Cancers

Supportive Care

Lung Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Advances in CAR T-Cell Therapy for Patients With Hematologic Malignancies

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Multitumor.

Target Audience
This program is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Recall the scientific rationale, key evidence, and expanding role of current and emerging CAR T-cell therapies in lymphomas, leukemias, and myeloma
  • Implement proactive strategies for monitoring and managing toxicities associated with CAR T-cell therapies in patients with lymphomas, leukemias, and myeloma
  • Assess patient access to supportive care before, during, and after CAR T-cell therapy, in order to more promptly address barriers to optimal outcomes
  • Initiate discussions with patients on toxicities of CAR T-cell therapies, providing information and resources on their appropriate management and when and who to contact on the healthcare team if they have new or worsening symptoms
  • Integrate strategies to foster equitable access to CAR T-cell therapies for patients with lymphomas, leukemias, or myeloma, both in the clinic and in clinical trials

Strengthening the Safety Net With Advanced Nursing Strategies for Managing Immunotherapy-Related Adverse Events

Goal Statement
To enhance learners' knowledge, confidence, and clinical expertise in proactively managing immune-related adverse events in cancer patients undergoing immunotherapy, ultimately driving improved patient care, safety, and treatment outcomes. 

Target Audience
This program is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Develop a proactive nursing care plan for early identification and effective management of immune-related adverse events (irAEs) from ICI and ICI-targeted therapy combinations, focusing on maintaining quality of life, treatment adherence, and interdisciplinary collaboration
  • Differentiate between immune-related and targeted therapy-associated adverse events to guide appropriate nursing interventions and patient care strategies
  • Apply current guidelines for adjusting or withholding immunotherapy in response to adverse events, ensuring safe and effective patient care during ICI combination treatments
  • Educate patients on recognizing and promptly reporting signs and symptoms of irAEs, providing them with resources to support informed self-management

Clinic-Ready Insights on Emerging Data for Current Antibody–Drug Conjugates in Breast Cancer

Goal Statement
This program aims to improve learners’ knowledge and competence in safely and effectively incorporating antibody–drug conjugates into personalized care of patients with breast cancer.

Target Audience
This program is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Integrate patients’ treatment goals, preferences, and quality of life considerations into decisions related to ADC therapy selection and supportive care
  • Recommend treatment options incorporating ADCs to appropriate patients with breast cancer based on the latest evidence, approvals, and guidelines
  • Educate patients and colleagues on the latest ADC safety data and how an ADC’s safety profile is related to its structural, mechanistic, and other unique characteristics
  • Plan evidence-based strategies for monitoring and managing AEs related to ADC therapy using the latest evidence, guidelines, and expert recommendations

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.0 contact hours, including 3.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 3.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Advances in CAR T-Cell Therapy for Patients With Hematologic Malignancies

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Clinical Care Options, LLC (CCO) and Practicing Clinicians Exchange (PCE).

Supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.


Strengthening the Safety Net With Advanced Nursing Strategies for Managing Immunotherapy-Related Adverse Events

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Clinical Care Options, LLC (CCO) and Practicing Clinicians Exchange (PCE).

Supported by educational grants from Bristol Myers Squibb and Merck Sharp & Dohme LLC.


Clinic-Ready Insights on Emerging Data for Current Antibody–Drug Conjugates in Breast Cancer

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Clinical Care Options, LLC (CCO) and Practicing Clinicians Exchange (PCE).

This program has been supported by an independent educational grant from Gilead Sciences, Inc.